Pharm Exec profiles five recent drug launches and announces winners of first annual APEX Awards.
In this issue of Pharmaceutical Executive, we profile five brands that recently launched—each with a unique aspect of marketing and advertising to ensure visibility and prescription sales. And what better way to highlight the importance of these campaigns but to announce the winners of our first annual Pharm Exec APEX Awards.
As part of our mission to ensure our readers “Master the Science of Success,” we are committed to delivering that marketing and advertising know-how and devoting specific attention so this area receives its fair share for the commercial success of a new prescription therapy. This past year definitely heralded the clinical development and regulatory successes needed to get vaccines into the hands of the global population. However, during the pandemic, commercialization of other therapies didn’t stop, as many drugs became available with marketers, agencies, and manufacturers pivoting to get the word out to patients and physicians alike.
As our CEO Mike Hennessy Jr. notes in the Pharmaceutical Executive™ APEX Awards Celebrating RxCellence 2021, the tenacity, dedication, and sheer passion of the healthcare marketer “for delivering extraordinary advertising in the face of the past year’s events have made our first annual event a truly positive one for the history books.”
What makes the Pharmaceutical Executive™ APEX Awards special is that the work isn’t judged by agency peers, but by actual healthcare professionals. The audience that sees these materials every day. After all, for decades agencies and marketers have invited everyone from general practitioners to seasoned specialists to sit through endless hours of research to determine if the work is relevant and effective. If you didn’t have a chance to watch our virtual awards event last night, you can watch it on-demand here: https://bit.ly/3jsn2j4.
As mentioned, we are expanding our resources toward pharma marketing to make sure the C-suite stays on top of trends and changes in this specialized area. To that end, please meet Fran Pollaro, Pharm Exec’s newest Senior Editor, dedicated to covering the pharma marketing market. Fran’s column debut is on page 14, where he highlights recent unbranded vaccine campaigns as a mirror to the success unregulated campaigns can mean to pre-launch and launch activities.
Also, Fran was co-master of ceremonies for our virtual APEX Awards, along with our Group Publisher Todd Baker. Along with that public-facing role, Fran will cover news, commission articles, and update people moves on the Sales and Marketing topic of our website, www.pharmexec.com/topic/sales-marketing.
We will be debuting the Pharm Exec Marketing Direct enewsletter within the next six weeks. Make sure you sign up to receive your biweekly update!
Lisa Henderson is Pharm Exec’s Editor-in-Chief. She can be reached at lhenderson@mjhlifesciences.com.
Novel GLP-1 Receptor Agonist Demonstrates Promising Results Treating Patients with Obesity
January 21st 2025Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a half-life of up to 60 hours, and superior pharmacokinetic properties compared to other oral GLP-1 receptor agonists.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
January 20th 2025Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS G12C-mutated metastatic colorectal cancer.